Skip to main content
OpenTrials
Completed

NCT Number: NCT05959811

Meridian Yoga on Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect in breast cancer patients with completion of chemotherapy, and that is characterized by associated clinical symptoms such as pain, tingling, numbness, and paresthesia etc. CIPN also interferes with patients' functions of daily living and leads to chronic functional decline and a reduced quality of life. Meridian yoga is beneficial to the treatment of patients with peripheral neuropathy and the improvement of their quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

China Medical University, Taiwan

Taichung, 404, Taiwan

About this study

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect in breast cancer patients with completion of chemotherapy, and that is characterized by associated clinical symptoms such as pain, tingling, numbness, and paresthesia etc. CIPN also interferes with patients' functions of daily living and leads to chronic functional decline and a reduced quality of life. Meridian yoga is beneficial to the treatment of patients with peripheral neuropathy and the improvement of their quality of life.

Therefore, the aim of this study was to evaluate the efficacy of meridian yoga for CIPN in breast cancer patients. The investigators designed a clinical randomized controlled trial in which 80 patients with CIPN were equally divided into a control group (8 weeks of general care) and a treatment group (general care plus 16 times yoga interventions for 8 weeks). The assessment time was before (vision 1) and at the completion of 8 weeks of Meridian yoga treatment (vision 2). The primary outcome was the change in scores of the neuropathic pain scale (Chinese version). The secondary outcome was to the changes of meridian energy [Meridian Energy Analyzer (M.E.A.D.)], Perfusion Index (PI) value of peripheral blood flow, and the changes of cortisol and IL-6 level in salivary fluid.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chinese or Taiwanese-proficient men and women aged ≥18 years.
  • Patients with stage I-III breast cancer.
  • Suffering from peripheral neuropathy caused by chemotherapy (professional judgment by a physician).
  • Willing to adhere to requirement that no new pain medication be taken throughout the study period.
  • Willing to adhere to all study-related procedures, including randomization to one of the two arms.
  • Patient answers "Yes" to at least one factor in the question: "Do participants think your balance, gait, posture, alignment, or flexibility has been affected by your experience of CIPN?"

Exclusion criteria

  • Metastatic disease.
  • Drugs abuse such as amphetamines, morphine, etc.
  • Pregnant
  • Those with severe mental illness or mental instability who cannot cooperate with the trial.
  • People who are severely hearing impaired, visually impaired, or demented and unable to perform yoga.
  • Severe heart disease or chronic obstructive lung disease, liver or kidney failure,and edema or severe skin damage.
  • Severe spinal disease, affecting actors.
  • Those who have participated in yoga practice in the past month.
  • Those who do not sign the informed consent.

Treatment and study plan

yoga

Other

60 minutes yoga practice ,twice a week for 8 weeks

Primary outcomes

  1. Neuropathic Pain Scale

    Time frame: Change from baseline of Neuropathic Pain Scale at 8 weeks.

    The questionnaire explores the performance of patients with neuropathic pain and nociceptive pain in different pain types in this questionnaire, and has appropriate reliability and validity, among which, specific pain performance, for different types of pain and changes in nerve conduction examination have special performance.

    This questionnaire is NPSI-T(Chinese version of neuropathic pain symptom inventory). It consists of 12 questions, all of which address pain on a scale of 0-10. Higher scores mean a worse outcome.

Secondary outcomes

  1. Peripheral perfusion index

    Time frame: Change from baseline Peripheral perfusion index at 8 weeks.

    The investigators expected to observe changes in peripheral perfusion values to reflect the correlation between peripheral blood flow and peripheral neuropathy.

    The normal value of Peripheral perfusion index(PPI) was suggested to range between 0.2 and 20%.Higher Peripheral perfusion index values reflects better peripheral tissue perfusion.

Other outcomes

  1. Salivary Cortisol level

    Time frame: Change from baseline Salivary cortisol level at 8 weeks.

    Cortisol plays an important role in the energy metabolism, and is regarded as one of the main stress hormones.

  2. Interleukin-6(IL-6) level

    Time frame: Change from baseline Salivary Interleukin-6(IL-6) level at 8 weeks.

    The investigators suggest that Interleukin-6(IL-6) signaling may be an important biological mechanism associated with the persistence of painful CIPN symptoms

  3. Meridian Energy Analyzer

    Time frame: Change from baseline at 8 weeks.

    The investigators use the Meridian Monitoring System test to detect changes in the conductivity of the skin on the surface of the meridians, in order to judge the changes in the energy of the mWeeridians of the body.

Sponsors and collaborators

Lead sponsor

China Medical University Hospital

Other

Registry information

Acronym: CIPN

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Jul 25, 2023
Registry last updated
Feb 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.